Core Viewpoint - IQVIA Holdings Inc. is identified as one of the most undervalued AI stocks currently available for investment, supported by positive analyst and hedge fund sentiment, as well as a low forward price-to-earnings ratio [1] Financial Performance - For the fourth quarter, IQVIA reported a revenue growth of 10.30%, reaching $4.36 billion [5] - The company's R&D backlog increased to $32.70 billion, with a book-to-bill ratio of 1.18x [5] - Adjusted EPS for the quarter was $3.42, reflecting a 9.60% increase [5] - Looking forward, IQVIA anticipates revenue between $17.15 billion and $17.35 billion, and adjusted EPS between $12.55 and $12.85 [5] Analyst Ratings and Price Targets - Mizuho lowered its price target for IQVIA from $266 to $215 while maintaining an 'Outperform' rating [2] - Truist reduced its price target from $290 to $245 and cut its forward EBITDA multiple from 14x to 13x due to AI-related concerns, while still holding a 'Buy' rating [4]

Investment Rating - The report emphasizes the importance of integrating electronic clinical outcome assessments (eCOAs) into oncology trials to meet regulatory guidelines and payer expectations, while minimizing patient burden [5]. Core Insights - The report highlights a shift towards patient-centered drug development in oncology, driven by regulatory initiatives such as the FDA's Project Optimus, which emphasizes the need for capturing patient experiences alongside traditional clinical outcomes [4][11]. - It identifies five key aspects of patient experience that should be measured in oncology trials, including disease-related symptoms, adverse events, overall impact of side effects, physical functioning, and role functioning [16][19]. - The report advocates for the use of eCOAs to enhance data collection efficiency and patient engagement, suggesting strategies such as using familiar devices, providing context for assessments, and ensuring ease of use [26][27][25]. Summary by Sections Patient Experience - Patient feedback is crucial for understanding the impact of treatments on their lives, and it adds significant value to drug development and evaluation [7]. - The FDA encourages the inclusion of appropriate clinical outcome assessments (COAs) to capture key patient experience elements, which are essential for regulatory submissions [11]. eCOA Strategies and Best Practices - The report outlines several recommendations for implementing eCOA strategies effectively, including: - Starting with a scientifically sound COA strategy to ensure relevant and efficient data collection [23]. - Considering decentralized clinical trials to reduce patient burden and enhance compliance [22]. - Allowing patients to use their own devices (BYOD) to facilitate participation and improve data collection rates [26]. - Providing patients with context about how their contributions to eCOAs benefit research, reinforcing the value of their participation [27]. Data Collection and Regulatory Compliance - The report stresses the importance of minimizing patient burden in data collection, suggesting that assessments should be relevant and not overly frequent [12][13]. - It emphasizes that the choice of assessment tools should align with regulatory expectations and capture valuable insights while respecting patients' time and energy constraints [18][19].

Investment Rating - The report indicates a favorable investment outlook for emerging biopharmaceutical companies (EBPs), highlighting a unique opportunity for self-commercialization to maximize asset value [6][11]. Core Insights - The healthcare system is increasingly led by digital-savvy decision-makers who demand faster, more relevant, and personalized information, fundamentally altering traditional pharmaceutical market models [5][10]. - EBPs can leapfrog traditional commercial infrastructures to adopt a streamlined, technology-driven business model that allows for rapid, agile, and precise engagement, even in smaller markets [6][9]. - The report emphasizes the importance of leveraging modern data management and technology to support the new ecosystem of commercial models, enabling EBPs to navigate complex market dynamics effectively [35][40]. Summary by Sections 1. Introduction - The report discusses the significant advancements in drug therapies and the role of EBPs in translating scientific breakthroughs into potential therapies, accounting for 70% of clinical trial assets and over half of new active substances launched in the past two decades [9]. 2. New Era of Commercialization - The report outlines the compression of asset lifecycles and the increasing evidence thresholds that innovators face, necessitating a shift in commercialization strategies [14][15]. - It highlights the emergence of diverse and demanding customers, requiring EBPs to adapt to new market dynamics and engage with a broader range of stakeholders [15][16]. 3. Golden Opportunities in Ecosystem Business Models (EBP) - EBPs are positioned to capitalize on a transformative moment by adopting advanced, technology-enabled commercial models that enhance speed, agility, and precision in market entry [6][18]. - The report identifies three strategic options for EBPs to unlock asset value: self-commercialization, co-commercialization with partners, or licensing assets to third parties [30][31][32]. 4. Foundations of New Models - The report emphasizes the need for EBPs to build a modern data architecture that supports flexible and dynamic organizational structures, enabling them to respond effectively to market changes [40][41]. - It discusses the importance of integrating technology and data analytics into core business processes to enhance operational efficiency and decision-making [37][38]. 5. Technology-Enabled Business Models - The report outlines the characteristics of a modern, technology-driven business model, focusing on maximizing speed, flexibility, and precision while minimizing fixed costs [57][58]. - It stresses the necessity for EBPs to partner with technology-centric outsourcing providers to mitigate risks associated with building enabling infrastructures [60][63]. 6. Full-Service Outsourcing Partnerships - The report highlights the advantages of full-service outsourcing partnerships, which can alleviate the burden of establishing local operations and managing multiple external partners, thus minimizing fixed cost exposure [67][70]. - It provides examples of successful collaborations that have enabled EBPs to effectively commercialize their assets in various markets [79][80].

Core Insights - The article discusses IQVIA Holdings Inc.'s recent performance, highlighting a revenue of $4.017 billion in Q2, which was driven by growth in the Technology & Analytics Solutions (TAS) segment [1]. Company Performance - IQVIA reported a revenue of $4.017 billion in Q2, indicating a strong performance compared to previous quarters [1]. - The growth in revenue is primarily attributed to the Technology & Analytics Solutions (TAS) segment, suggesting a focus on innovative solutions within the healthcare sector [1]. Investment Focus - The article emphasizes the importance of innovative companies in the biotech and pharmaceutical sectors, particularly those developing breakthrough therapies with potential acquisition catalysts [1].

Group 1 - IQVIA Holdings Inc. is considered a strong buy in the healthcare sector, with recent price target adjustments from various firms following its fiscal Q4 report [1][2] - Mizuho reduced its price target for IQVIA from $266 to $215 while maintaining an Outperform rating, and Truist lowered its target from $290 to $245, updating their models due to re-segmentation after Q4 earnings [1] - TD Cowen cut its price target from $245 to $174, maintaining a Hold rating, and noted that while AI risks exist, their long-term impact on Contract Research Organizations (CROs) is not fully understood [2] Group 2 - IQVIA Holdings provides advanced analytics, clinical research services, and technology solutions specifically for the life sciences industry, with operations divided into three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions [3]

Core Insights - The discussion focuses on the performance of the TAS segment, highlighting a 7% growth in constant currency for the fourth quarter [2]. Group 1: Company Performance - The TAS segment experienced a notable growth of 7% in constant currency during the fourth quarter [2]. - Consulting services are emphasized as a key area of focus, particularly in relation to AI initiatives [2].

Summary of the Conference Call Company and Industry Overview - The conference call was held during the Citi MedTech Access Day, focusing on the MedTech industry and the company’s performance in the fourth quarter. - The company reported a strong fourth quarter with a growth of approximately 7% in constant currency and nearly 10% in actual currency, driven by the Tools and Diagnostics (TAS) segment [8][9]. Key Financial Highlights - The TAS segment's real-world business grew double digits, while consulting and analytics grew in the low- to mid-single-digit range [9]. - The legacy TAS breakdown includes approximately one-third from real-world, one-quarter from information, 20% from consulting, and the remainder from technology [13]. - The new Commercial Solutions segment is expected to grow by 8%, while R&DS is projected to grow at 4% [16][24]. - The company anticipates about 150 basis points of growth from M&A contributions, primarily in Commercial Solutions [24]. Growth Drivers and Market Dynamics - The company noted improvements in client decision-making and a healthy pipeline, particularly in drug launches, which are key growth drivers [21]. - The Cedar Gate acquisition is highlighted as a strategic move to enhance the payer and provider segment within the real-world patient solutions [21]. - There is a trend of pharma clients consolidating vendors, leading to increased outsourcing of commercial operations, which the company is well-positioned to capitalize on [30][32]. AI and Data Strategy - The company views AI as an opportunity rather than a threat, emphasizing the need for proprietary data, domain expertise, and technology to effectively deploy AI solutions [44]. - The proprietary nature of the company’s data, which is messy, dynamic, and complex, serves as a competitive moat against potential AI competitors [46][48]. - The company has developed 150 different AI agents covering 30 use cases, indicating a strong focus on integrating AI into their offerings [57]. Consulting Business and AI Impact - While some areas of the consulting business may be impacted by AI, the overall opportunities are expected to outweigh the losses [71]. - The potential revenue at risk from AI is estimated at around $100 million, primarily from low-end consulting work [74]. - The company is modernizing its offerings with AI tools to retain clients and enhance value [74]. Financial Metrics and Guidance - The company experienced elevated cancellations in 2024, primarily due to specific study-related events, but expects a return to normal levels in 2025 [106]. - The gross bookings environment appears healthy, with positive indicators from both pharma and biotech sectors [118]. - The pricing environment is stable, with the company maintaining disciplined pricing strategies [134]. Capital Deployment and Leverage - The company is comfortable with a leverage ratio in the 3-4 range and remains opportunistic regarding acquisitions and share repurchases [141][142]. - The incoming CFO emphasized continuity in financial discipline and high standards across the organization [143]. Conclusion - The company is optimistic about its growth prospects, driven by strong performance in the TAS segment, strategic acquisitions, and the integration of AI into its operations. - The focus on proprietary data and client relationships positions the company well to navigate the evolving landscape of the MedTech industry.

Core Insights - Broyhill Asset Management's fourth-quarter 2025 investor letter highlights extreme market concentration and a strong focus on artificial intelligence, resulting in many sectors being left behind [1] - The portfolio has been significantly reshaped and now trades at a substantial discount compared to the broader market, with the firm expecting to benefit as market fundamentals improve [1] - The portfolio declined by 1.4% for the year, underperforming the MSCI ACWI's 22.9% return, indicating a market dominated by momentum rather than fundamentals [1] Company Highlights - IQVIA Holdings Inc. (NYSE:IQV) is identified as one of the top contributors to Broyhill's portfolio, recognized for its role as a leading provider of clinical research services and healthcare intelligence [2][3] - As of February 25, 2026, IQVIA's stock closed at $161.91 per share, with a one-month return of -31.28% and a 52-week loss of 13.18%, while its market capitalization stands at $27.573 billion [2] - The company is noted for its durable business model and identifiable catalysts that the market has mispriced, contributing meaningfully as fears around biotech funding and clinical activity began to ease [3] Market Sentiment - Despite IQVIA's potential, it is not among the 30 most popular stocks among hedge funds, with 69 hedge fund portfolios holding the stock at the end of Q4, up from 61 in the previous quarter [4] - The sentiment towards the biotech sector remains fragile, but IQVIA's critical role in drug development is considered unchallenged, with expectations for a recovery in the industry [3] - The firm suggests that certain AI stocks may offer greater upside potential and less downside risk compared to IQVIA, indicating a competitive landscape for investment opportunities [4]

Investment Rating - The report does not explicitly provide an investment rating for the biosimilar industry or ophthalmology sector Core Insights - The biosimilar market is expected to grow significantly, particularly with the introduction of aflibercept biosimilars, which could lead to substantial cost savings and improved patient outcomes in ophthalmology [3][23][24] - The report emphasizes the importance of addressing barriers to biosimilar adoption, including stakeholder education and awareness, to unlock the full potential of biosimilars in the healthcare system [11][18][67] Overview - Biologic medicines account for over 40% of total pharmaceutical spending in the EU, up from 28% in 2014, highlighting the financial pressures on healthcare systems [9][25] - Biosimilars currently represent only 5% of biologics spending, yet they have contributed €75 billion in cumulative savings in Europe and enabled over 9 billion treatment days [9][30] - The upcoming loss of exclusivity for 69 biologics between 2024 and 2030 presents a significant opportunity for biosimilars, with an estimated pre-expiry value of €28 billion [11][35] Ophthalmology Treatment Landscape and Challenges - The prevalence of age-related macular degeneration (AMD) is projected to rise by 15% by 2050, affecting approximately 67 million Europeans in 2022 [12][45] - Current treatment for retinal diseases is dominated by intravitreal anti-VEGF therapies, which require frequent injections and follow-ups, leading to capacity constraints in ophthalmology systems across Europe [13][16] - The introduction of biosimilars could alleviate capacity pressures by generating cost savings that can be reinvested into healthcare systems [14][58] Stakeholder Perspectives on Biosimilars and Barriers to Adoption - Interviews with 142 stakeholders revealed low confidence and limited use of biosimilars in ophthalmology, with confidence scores ranging from 2/7 in France, Germany, and Spain to 5.5/7 in the UK [15][61] - Key barriers to adoption include limited stakeholder experience, concerns about comparability, and fragmented decision-making processes [17][67] - Education campaigns targeting clinicians and other stakeholders are essential to build trust and address misconceptions about biosimilars [18][19] Overcoming Barriers to Biosimilar Adoption - Comprehensive education campaigns should focus on the principles of biosimilarity, regulatory rigor, and clinical comparability to enhance clinician confidence [18][19] - Strengthening the evidence base with accessible data on clinical performance and cost-effectiveness is critical for informed decision-making [19][20] - Reinvesting savings from biosimilars into ophthalmology services can incentivize providers and improve access to care [21][24]

Core Insights - IQVIA Holdings Inc. is recognized as one of the top 10 life sciences stocks to buy according to hedge funds, indicating strong market interest and potential [1] - Analysts have adjusted their price targets for IQVIA following the company's fourth-quarter results, reflecting changes in market conditions and company performance [2][3] Analyst Ratings and Price Targets - Jailendra Singh from Truist Financial has reiterated a Buy rating for IQVIA, lowering the price target from $290 to $274, which still suggests an upside potential of over 65% [1][2] - Charles Rhyee from TD Cowen has maintained a Hold rating, reducing the price target from $245 to $174, acknowledging potential long-term risks associated with AI but noting current uncertainties [3] Company Overview - IQVIA Holdings Inc. provides a range of services including clinical research, advanced analytics, commercial insights, and market intelligence to the healthcare and life sciences sectors globally [4] - The company specializes in end-to-end clinical trials, offering services such as protocol design, site selection, recruitment, and data analysis, along with cloud-based commercial solutions [4]